Table 1: Cytotoxicity and antiviral activity of derivatives 4a,b,c,d-7a,b,c,d against CV-B5 and Sb-1. Data represent mean values of three independent determinations. Pleconaril was used as a positive control.
Compounds |
Vero76 |
CV-B5 |
Sb-1 |
Ref. |
- |
aCC50 |
bEC50 |
- |
- |
4a |
60 |
>60 |
42 |
[15] |
4b |
>100 |
>100 |
>100 |
[15] |
4c |
>100 |
42 |
19 |
- |
4d |
>100 |
>100 |
>100 |
[16] |
5a |
71 |
28 |
>71 |
[15] |
5b |
>100 |
>100 |
>100 |
[15] |
5c |
>100 |
41 |
50 |
- |
5d |
>100 |
>100 |
>100 |
[16] |
6a |
>100 |
30 |
47 |
[15] |
6b |
>100 |
10 |
>100 |
[15] |
6c |
>100 |
11 |
37 |
- |
6d |
>100 |
>100 |
>100 |
[16] |
7a |
>100 |
>100 |
>100 |
[15] |
7b |
>100 |
30 |
53 |
[15] |
7c |
>100 |
10.2 |
3.8 |
- |
7d |
>100 |
>100 |
>100 |
[16] |
Ref. compounds |
- |
- |
- |
- |
Pleconaril |
77±6.8 |
0.005±0.002 |
2±0.6 |
- |
aCompound concentration (µM) required to reduce the viability of mock-infected Vero76 monolayers by 50%. bCompound concentration (µM) required to reduce the plaque number of the indicated virus by 50% in Vero76 monolayers.